{"id":"https://openalex.org/W2065886331","doi":"https://doi.org/10.1517/14656566.2014.876992","title":"New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","display_name":"New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","alternate_titles":[],"publication_year":2014,"publication_date":"2014-01-16","ids":{"openalex":"https://openalex.org/W2065886331","doi":"https://doi.org/10.1517/14656566.2014.876992","mag":"2065886331","pmid":"https://pubmed.ncbi.nlm.nih.gov/24428677"},"language":"en","primary_location":{"id":"doi:10.1517/14656566.2014.876992","doi":"https://doi.org/10.1517/14656566.2014.876992","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2014.876992","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2065886331"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036163332","display_name":"Amirhossein Sahebkar","orcid":"https://orcid.org/0000-0002-8656-1444","observed_orcids":["https://orcid.org/0000-0002-8656-1444","https://orcid.org/0000-0003-1747-8353"]},"institutions":[{"id":"https://openalex.org/I165560825","display_name":"Mashhad University of Medical Sciences","ror":"https://ror.org/04sfka033","country_code":"IR","type":"education","lineage":["https://openalex.org/I165560825"]}],"countries":["IR"],"is_corresponding":false,"raw_author_name":"Amirhossein Sahebkar","raw_affiliation_strings":["Biotechnology Research Center, Mashhad University of Medical Sciences , Mashhad , Iran"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biotechnology Research Center, Mashhad University of Medical Sciences , Mashhad , Iran","institution_ids":["https://openalex.org/I165560825"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108380080","display_name":"Gerard T. Chew","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I2799740997","display_name":"Royal Perth Hospital","ror":"https://ror.org/00zc2xc51","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2799740997","https://openalex.org/I2800882159","https://openalex.org/I4388446364","https://openalex.org/I4405257575"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Gerard T Chew","raw_affiliation_strings":["School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Australia","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I2799740997"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079564889","display_name":"Gerald Francis Watts","orcid":"https://orcid.org/0000-0003-2276-1524","observed_orcids":["https://orcid.org/0000-0003-2276-1524"]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I2799740997","display_name":"Royal Perth Hospital","ror":"https://ror.org/00zc2xc51","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2799740997","https://openalex.org/I2800882159","https://openalex.org/I4388446364","https://openalex.org/I4405257575"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Gerald F Watts","raw_affiliation_strings":["Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital and Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, GPO Box X2213, Perth, Western Australia 6847, Australia +61 8 92240245; +61 8 92240246; gerald.watts@uwa.edu.au","University of Western Australia, Perth, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital and Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, GPO Box X2213, Perth, Western Australia 6847, Australia +61 8 92240245; +61 8 92240246; gerald.watts@uwa.edu.au","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I2799740997"]},{"raw_affiliation_string":"University of Western Australia, Perth, Australia","institution_ids":["https://openalex.org/I177877127"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.3686,"has_fulltext":false,"cited_by_count":190,"citation_normalized_percentile":{"value":0.92170729,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"15","issue":"4","first_page":"493","last_page":"503"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12975","display_name":"Paraoxonase enzyme and polymorphisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/peroxisome-proliferator-activated-receptor-agonists","display_name":"peroxisome proliferator-activated receptor agonists","score":0.9559999704360962},{"id":"https://openalex.org/keywords/atherogenic-dyslipidemia","display_name":"atherogenic dyslipidemia","score":0.9259999990463257},{"id":"https://openalex.org/keywords/non-alcoholic-fatty-liver-disease","display_name":"non-alcoholic fatty liver disease","score":0.9980000257492065},{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.9390000104904175},{"id":"https://openalex.org/keywords/fenofibrate","display_name":"fenofibrate","score":0.9599999785423279},{"id":"https://openalex.org/keywords/gw501516","display_name":"GW501516","score":0.9079999923706055},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.675000011920929},{"id":"https://openalex.org/keywords/hepatic-lipid-accumulation","display_name":"hepatic lipid accumulation","score":0.7350000143051147},{"id":"https://openalex.org/keywords/cardiovascular-outcomes","display_name":"cardiovascular outcomes","score":0.42899999022483826}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7888518571853638},{"id":"https://openalex.org/C2778110834","wikidata":"https://www.wikidata.org/wiki/Q419724","display_name":"Fenofibrate","level":2,"score":0.6940566897392273},{"id":"https://openalex.org/C2779478299","wikidata":"https://www.wikidata.org/wiki/Q2335423","display_name":"Steatohepatitis","level":4,"score":0.6896376013755798},{"id":"https://openalex.org/C2778096610","wikidata":"https://www.wikidata.org/wiki/Q1476525","display_name":"Dyslipidemia","level":3,"score":0.674770176410675},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.5870741009712219},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5650203227996826},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.5520404577255249},{"id":"https://openalex.org/C7341990","wikidata":"https://www.wikidata.org/wiki/Q10331450","display_name":"PPAR agonist","level":4,"score":0.5051353573799133},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.4889320433139801},{"id":"https://openalex.org/C2776954865","wikidata":"https://www.wikidata.org/wiki/Q1546498","display_name":"Nonalcoholic fatty liver disease","level":4,"score":0.48066914081573486},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4776245951652527},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45040756464004517},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.439301460981369},{"id":"https://openalex.org/C2778657065","wikidata":"https://www.wikidata.org/wiki/Q417997","display_name":"Ezetimibe","level":3,"score":0.42378681898117065},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.29056766629219055},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.2635110914707184},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2615475058555603},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.24186444282531738},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.22466716170310974}],"mesh":[{"descriptor_ui":"D000085","descriptor_name":"Acetates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005234","descriptor_name":"Fatty Liver","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005234","descriptor_name":"Fatty Liver","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007333","descriptor_name":"Insulin Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008075","descriptor_name":"Lipoproteins, HDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008076","descriptor_name":"Cholesterol, HDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011422","descriptor_name":"Propionates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D047188","descriptor_name":"Chalcones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047492","descriptor_name":"Peroxisome Proliferator-Activated Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047492","descriptor_name":"Peroxisome Proliferator-Activated Receptors","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D065626","descriptor_name":"Non-alcoholic Fatty Liver Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1517/14656566.2014.876992","doi":"https://doi.org/10.1517/14656566.2014.876992","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14656566.2014.876992","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:24428677","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24428677","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:publications/8f6791b7-4869-47c9-a9ce-d2c53fd843d2","doi":null,"is_oa":false,"landing_page_url":"https://admin.research-repository.uwa.edu.au/en/publications/8f6791b7-4869-47c9-a9ce-d2c53fd843d2","pdf_url":null,"source":{"id":"https://openalex.org/S4306402492","display_name":"UWA Profiles and Research Repository (UWA)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Sahebkar, A, Chew, G & Watts, G 2014, 'New peroxisome proliferator-Activated receptor agonists: Potential treatments for atherogenic Dyslipidemia and non-Alcoholic fatty liver disease', Expert Opinion on Pharmacotherapy, vol. 15, no. 4, pp. 493-503. https://doi.org/10.1517/14656566.2014.876992","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:oai:pure.atira.dk:publications/e0d0b5c2-48f9-4a8d-95c9-c5893fcd7c2b","doi":null,"is_oa":false,"landing_page_url":"https://research-repository.uwa.edu.au/en/publications/e0d0b5c2-48f9-4a8d-95c9-c5893fcd7c2b","pdf_url":null,"source":{"id":"https://openalex.org/S4306402492","display_name":"UWA Profiles and Research Repository (UWA)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Sahebkar, A, Chew, G & Watts, G 2014, 'New peroxisome proliferatoractivated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease', Expert Opinion on Pharmacotherapy, vol. 15, pp. 493-503.","raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":70,"referenced_works":["https://openalex.org/W71678318","https://openalex.org/W1963683487","https://openalex.org/W1973573989","https://openalex.org/W1974139741","https://openalex.org/W1977041568","https://openalex.org/W1990055069","https://openalex.org/W1993063661","https://openalex.org/W1997759488","https://openalex.org/W2001364660","https://openalex.org/W2001736262","https://openalex.org/W2007755423","https://openalex.org/W2008497553","https://openalex.org/W2014180706","https://openalex.org/W2015643123","https://openalex.org/W2019280401","https://openalex.org/W2022174018","https://openalex.org/W2024035093","https://openalex.org/W2028145176","https://openalex.org/W2028316975","https://openalex.org/W2028933018","https://openalex.org/W2029462689","https://openalex.org/W2030551858","https://openalex.org/W2039105369","https://openalex.org/W2056260385","https://openalex.org/W2060476304","https://openalex.org/W2062262659","https://openalex.org/W2064715676","https://openalex.org/W2066841620","https://openalex.org/W2069412892","https://openalex.org/W2071298734","https://openalex.org/W2077621811","https://openalex.org/W2079454650","https://openalex.org/W2080567142","https://openalex.org/W2081070477","https://openalex.org/W2092700213","https://openalex.org/W2093336561","https://openalex.org/W2097511872","https://openalex.org/W2099966991","https://openalex.org/W2100641739","https://openalex.org/W2102210313","https://openalex.org/W2102675827","https://openalex.org/W2103156933","https://openalex.org/W2104359225","https://openalex.org/W2105407506","https://openalex.org/W2108492797","https://openalex.org/W2120312841","https://openalex.org/W2125344994","https://openalex.org/W2128458878","https://openalex.org/W2128460332","https://openalex.org/W2132064529","https://openalex.org/W2132600168","https://openalex.org/W2134120087","https://openalex.org/W2135729475","https://openalex.org/W2140038597","https://openalex.org/W2144259092","https://openalex.org/W2145337164","https://openalex.org/W2149350026","https://openalex.org/W2150278188","https://openalex.org/W2155258805","https://openalex.org/W2159969745","https://openalex.org/W2162806924","https://openalex.org/W2164079954","https://openalex.org/W2165605025","https://openalex.org/W2165815833","https://openalex.org/W2167077309","https://openalex.org/W2169848635","https://openalex.org/W2170075604","https://openalex.org/W2171197951","https://openalex.org/W2172203327","https://openalex.org/W2589909250"],"related_works":["https://openalex.org/W2051656202","https://openalex.org/W2044593515","https://openalex.org/W2953485865","https://openalex.org/W4310595451","https://openalex.org/W3158110094","https://openalex.org/W2578706259","https://openalex.org/W7141594622","https://openalex.org/W2144259092","https://openalex.org/W4367839822","https://openalex.org/W3043449422"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Novel":[1],"peroxisome":[2],"proliferator-activated":[3],"receptor":[4],"(PPAR)":[5],"modulators":[6,9],"(selective":[7],"PPAR":[8,13,42,201],"[SPPARMs])":[10],"and":[11,30,44,56,91,113,127,141,153,174,196,207],"dual":[12,109,129],"agonists":[14,43,111,202],"may":[15,99],"have":[16,101,133],"an":[17],"important":[18],"role":[19],"in":[20,87,137,203],"the":[21,38,51,106,114,182,194],"treatment":[22,52,183],"of":[23,40,53,69,108,121,159,169,184,198],"cardiometabolic":[24],"disorders":[25],"owing":[26],"to":[27,192],"lipid-modifying,":[28],"insulin-sensitizing":[29,97],"anti-inflammatory":[31],"effects.":[32,104],"AREAS":[33],"COVERED:":[34],"This":[35],"review":[36],"summarizes":[37],"efficacy":[39,136,195],"new":[41,67,200],"SPPARMs":[45],"that":[46,71,166],"are":[47,161,190],"under":[48],"development":[49,107],"for":[50,75,181],"atherogenic":[54,89],"dyslipidemia":[55],"non-alcoholic":[57],"fatty":[58],"liver":[59,154],"disease":[60],"(NAFLD).":[61],"EXPERT":[62],"OPINION:":[63],"ABT-335":[64],"is":[65],"a":[66,81,93,128,178],"formulation":[68],"fenofibrate":[70],"has":[72,117],"been":[73,118],"approved":[74],"concomitant":[76],"use":[77],"with":[78,83,95],"statins.":[79],"K-877,":[80],"SPPARM-\u03b1":[82],"encouraging":[84],"preliminary":[85],"results":[86],"modulating":[88],"dyslipidemia,":[90],"INT131,":[92],"SPPARM-\u03b3":[94],"predominantly":[96],"actions,":[98],"also":[100],"favorable":[102],"lipid-modifying":[103],"Although":[105],"PPAR-\u03b1/\u03b3":[110],"(glitazars)":[112],"SPPARM-\u03b4":[115,125],"GW501516":[116],"abandoned":[119],"because":[120],"safety":[122,197],"issues,":[123],"another":[124],"(MBX-8025)":[126],"PPAR-\u03b1/\u03b4":[130],"agonist":[131],"(GFT-505)":[132],"shown":[134],"promising":[135,179],"decreasing":[138],"plasma":[139],"triglyceride":[140],"increasing":[142],"high-density":[143],"lipoprotein":[144],"cholesterol":[145],"concentrations,":[146],"as":[147,149],"well":[148],"improving":[150],"insulin":[151],"sensitivity":[152],"function.":[155],"The":[156],"beneficial":[157],"effects":[158],"GFT-505":[160],"complemented":[162],"by":[163],"preclinical":[164],"findings":[165],"indicate":[167],"reduction":[168],"hepatic":[170],"fat":[171],"accumulation,":[172],"inflammation":[173],"fibrosis,":[175],"making":[176],"it":[177],"candidate":[180],"NAFLD/nonalcoholic":[185],"steatohepatitis":[186],"(NASH).":[187],"Long-term":[188],"trials":[189],"required":[191],"test":[193],"these":[199],"reducing":[204],"cardiovascular":[205],"outcomes":[206],"treating":[208],"NAFLD/NASH.":[209]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2065886331","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":16},{"year":2023,"cited_by_count":16},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":21},{"year":2017,"cited_by_count":24},{"year":2016,"cited_by_count":27},{"year":2015,"cited_by_count":22},{"year":2014,"cited_by_count":8}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
